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Abstract
In mid November the biopharma industry was shocked by the announcement from Geron that they were ending
work on embryonic stem cell research and therapy. For more than 10 years the public image of all stem cell
research has been equated with embryonic stem cells. Unfortunately, a fundamentally important medical and
financial fact was being ignored: embryonic stem cell therapy is extremely immature. In parallel to efforts in
embryonic stem cell research and development, scientists and physicians in the field of adult stem cells realized
that the natural role of adult stem cells in the body is to promote healing and to act like endogenous “repair cells”
and, as a result, numerous companies have entered the field of adult stem cell therapy with the goal of expanding
numbers of adult stem cells for administration to patients with various conditions. In contrast to embryonic stem
cells, which are extremely expensive and potentially dangerous, adult cell cells are inexpensive and have an
excellent safety record when used in humans. Many studies are now showing that adult stem cells are practical,
patient-applicable, therapeutics that are very close to being available for incorporation into the practice of
medicine. These events signal the entrance of the field of stem cells into a new era: an era where hype and
misinformation no longer triumph over economic and medical realities.
Editorial
As with any major technological advancement, there is
an initial period of excitement and euphoria, followed
by a crash, followed by a solid steady advancement lead-
ing to life-changing advancement. It seems that the field
of stem cell research and clinical development is no
different.
In mid November the biopharma industry was shocked
by the announcement of Geron, the leader of embryonic
stem cell research and therapy, quitting work in this area.
This news was greeted by negative comments against the
whole industry such as “throwing stem cell research into
question” (ABC News) and “why would I want to invest
in a space where one of the most promising companies
just called it quits?” (San Francisco Business Times). It is
our position that this announcement is actually the
beginning of a new era in stem cell research and clinical
therapy, an era where hype and misinformation no longer
triumph over economic and medical realities.
Starting in the early 2000s a publicity campaign by
embryonic stem cell advocates managed to equate the
public image of all stem cell research as involving embryo-
nic stem cells. A debate quickly ensued that polarized the
pro-choice and pro-life communities, with statements
made equating to “if you don’t support embryonic stem
cells, you are not supporting cures for terrible disease such
as diabetes, Parkinson’s, and Alzheimer’s” or conversely,
accusations that “stem cell researchers are baby killers”.
While public attention was captivated by this debate, and
various State Governments created billion dollar funds to
support embryonic stem cell research, a fundamentally
important medical and financial fact was being ignored:
embryonic stem cells are extremely immature. To generate
adult organ, tissues or cells, the embryonic stem cell must
“fast forward” the process of years of maturation in a mat-
ter of weeks in order to create financially-valuable pro-
ducts. The second fundamental point is the propensity of
embryonic stem cells to form tumors called teratomas. In
fact, the scientific definition of an embryonic stem cell is a
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“cell that forms teratomas when placed in animals”. Thus
while everyone was arguing about the ethics of embryonic
stem cell research, the medical and economic realities
were ignored: specifically, it costs too much to create clini-
cal products from these cells. This did not stop the “bub-
ble” from growing. The promise of curing incurable
diseases with embryonic stem cells seems to have fixated
public attention, creating high valuations for companies in
this space.
Since 2006 investigators in academia and industry have
also been developing induced pluripotent stem cells as an
alternative to embryonic stem cells as starting material for
stem cell therapy. Induced pluripotent stem cells can be
produced from most adult cells and as a result using
induced pluripotent stem cells avoids the emotional polar-
ization associated with embryonic stem cells. Induced
pluripotent stem cells can also be produced from a
patient’s own cells, thus avoiding the potential problem of
developing therapies that are Human Leukocyte Antigen
(HLA) incompatible. Induced pluripotent stem cells, how-
ever, share many of the inherent problems associated with
embryonic stem cells, such as teratoma formation, diffi-
culty in inducing cell maturation and high costs associated
with their clinical application. Working with induced plur-
ipotent stem cells may, in fact, be more difficult and more
expensive than working with embryonic stem cells since
adult cells must be reprogrammed to produce induced
pluripotent stem cells and this likely must be done in a
way that avoids leaving a permanent molecular “foot
print” in the induced pluripotent stem cells. While
induced pluripotent stem cells have tremendous potential
for clinical stem cell therapy, more work is needed and the
golden era of induced pluripotent stem cells has not yet
arrived.
In parallel to efforts in embryonic and induced pluripo-
tent stem cell research and development, scientists and
physicians in the field of adult stem cells realized that the
natural role of adult stem cells in the body is to promote
healing, or in other words, to act like endogenous “repair
cells”. After a heart attack or stroke the body activates its
own adult stem cells in order to try to heal the damaged
tissue. In many cases the adult body does not have enough
stem cells to heal major injuries such as heart attacks. So
numerous companies have entered the field of adult stem
cell therapy with the goal of expanding numbers of adult
stem cells for administration to patients with various con-
ditions. In contrast to embryonic stem cells, which are
extremely expensive and potentially dangerous, adult cell
cells are inexpensive and have an excellent safety record
when used in humans.
Given that the difference between adult, embryonic and
induced pluripotent stem cells is not known to the general
public, this exit of Geron from the field of embryonic stem
cells has been erroneously interpreted by many as a
“major set back for stem cell research”. In contrast, noth-
ing could be further from the truth. Ironically, the same
day that Geron announced its exit from this field, the
adult stem cell company Mesoblast announced results of a
double-blind clinical study showing significant benefit in
heart failure patients receiving adult stem cells. This was
one of many studies showing that adult stem cells are a
practical, patient-applicable, therapeutics that are very
close to being available for incorporation into the practice
of medicine. From a financial perspective, major pharma-
ceutical companies have already placed their bets on adult
stem cells, including the $1.7 Billion Mesoblast-Cephalon
deal last year, the 1.3 billion dollar Osiris-Genzyme deal,
and Celgene-Anthrogenesis deal several years ago.
Thus, the field of stem cells is entering a new era: an
era in which companies will be judged on clinical and
financial practicality, not hype and manipulation of pub-
lic emotion.
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